The article compares small molecule drugs and biologics in development, cost, etc., questions biologic - preferential policies, and mentions related acts for policy correction.
Over the past decade, China's innovative drug market has experienced remarkable transformation and growth. With the combined drive of policies, technology, and capital, China's innovative drug industry has entered a golden period of growth. This paper pro
InnoCare announced the first patient dosing in the Phase III trial of ICP - 488 for psoriasis. It showed good results in Phase II, aiming to meet unmet needs.